View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2017	Jul. 28, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q2
Trading Symbol	MEDP
Entity Registrant Name	Medpace Holdings, Inc.
Entity Central Index Key	0001668397
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		39,486,848

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 29,055	$ 37,099
Restricted cash	275	308
Accounts receivable and unbilled, net (includes $1.2 million and $2.3 million with related parties at June 30, 2017 and December 31, 2016, respectively)	76,664	79,767
Prepaid expenses and other current assets	17,129	16,074
Total current assets	123,123	133,248
Property and equipment, net	45,244	43,805
Goodwill	660,981	660,981
Intangible assets, net	117,676	136,071
Deferred income taxes	11,536	97
Other assets	5,086	4,903
Total assets	963,646	979,105
Current liabilities:
Accounts payable	7,195	10,911
Accrued expenses	16,392	24,417
Pre-funded study costs (includes $1.5 million and $3.9 million with related parties at June 30, 2017 and December 31, 2016, respectively)	48,530	51,948
Advanced billings (includes $4.2 million and $7.6 million with related parties at June 30, 2017 and December 31, 2016, respectively)	65,577	65,668
Current portion of long-term debt	14,438	12,375
Other current liabilities	3,130	3,284
Total current liabilities	155,262	168,603
Long-term debt, net, less current portion	143,191	151,267
Deemed landlord liability, less current portion	27,591	28,527
Deferred income tax liability	481	12,030
Deferred credit	21,420
Other long-term liabilities	8,343	7,968
Total liabilities	356,288	368,395
Commitments and contingencies (see Note 11)
Shareholders’ equity:
Preferred stock - $0.01 par-value; 5,000,000 shares authorized; no shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively
Common stock - $0.01 par-value; 250,000,000 shares authorized at June 30, 2017 and December 31, 2016, respectively; 39,692,999 and 40,662,856 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively	398	407
Additional paid-in capital	627,407	623,629
Accumulated deficit	(18,419)	(9,584)
Accumulated other comprehensive loss	(2,028)	(3,742)
Total shareholders’ equity	607,358	610,710
Total liabilities and shareholders’ equity	$ 963,646	$ 979,105

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($) $ in Millions	Jun. 30, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Accounts receivable and unbilled, net with related parties	$ 1.2	$ 2.3
Pre-funded study costs with related parties	1.5	3.9
Advanced billings with related parties	$ 4.2	$ 7.6
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock shares authorized	5,000,000	5,000,000
Preferred stock shares issued	0	0
Preferred stock shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock shares authorized	250,000,000	250,000,000
Common stock shares issued	39,692,999	40,662,856
Common stock shares outstanding	39,692,999	40,662,856

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenue:
Service revenue, net (includes $2.9 million and $4.6 million with related parties for the three months ended June 30, 2017 and 2016, respectively, and $6.9 million and $12.4 million with related parties for the six months ended June 30, 2017 and 2016)	$ 94,552	$ 92,633	$ 188,333	$ 180,433
Reimbursed out-of-pocket revenue (includes $0.4 million and $1.7 million with related parties for the three months ended June 30, 2017 and 2016, respectively, and $1.1 million and $2.9 million with related parties for the six months ended June 30, 2017 and 2016)	11,664	13,321	24,494	25,107
Total revenue	106,216	105,954	212,827	205,540
Operating expenses:
Direct costs, excluding depreciation and amortization	51,955	49,234	103,060	96,215
Reimbursed out-of-pocket expenses (includes $0.4 million and $1.7 million with related parties for the three months ended June 30, 2017 and 2016, respectively, and $1.1 million and $2.9 million with related parties for the six months ended June 30, 2017 and 2016)	11,664	13,321	24,494	25,107
Selling, general and administrative	14,755	14,824	29,909	28,333
Depreciation	2,101	1,793	4,231	3,566
Amortization	9,462	12,668	18,910	25,336
Total operating expenses	89,937	91,840	180,604	178,557
Income from operations	16,279	14,114	32,223	26,983
Other expense, net:
Miscellaneous expense, net	(125)	(6)	(497)	(941)
Interest expense, net	(1,808)	(5,921)	(3,602)	(11,894)
Total other expense, net	(1,933)	(5,927)	(4,099)	(12,835)
Income before income taxes	14,346	8,187	28,124	14,148
Income tax provision	4,793	3,225	10,124	5,738
Net income	$ 9,553	$ 4,962	$ 18,000	$ 8,410
Net income per share attributable to common shareholders:
Basic	$ 0.24	$ 0.15	$ 0.44	$ 0.26
Diluted	$ 0.23	$ 0.15	$ 0.44	$ 0.26
Weighted average common shares outstanding:
Basic	40,183	32,636	40,425	32,631
Diluted	40,825	32,828	41,158	32,631

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Parenthetical) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Income Statement [Abstract]
Service revenue with related parties	$ 2.9	$ 4.6	$ 6.9	$ 12.4
Reimbursed out-of-pocket revenue with related parties	0.4	1.7	1.1	2.9
Reimbursed out-of-pocket expenses with related parties	$ 0.4	$ 1.7	$ 1.1	$ 2.9

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Statement Of Income And Comprehensive Income [Abstract]
Net income	$ 9,553	$ 4,962	$ 18,000	$ 8,410
Other comprehensive income (loss)
Foreign currency translation adjustments, net of taxes	1,118	(564)	1,714	8
Comprehensive income	$ 10,671	$ 4,398	$ 19,714	$ 8,418

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 18,000	$ 8,410
Adjustments to reconcile net income to net cash (used in) provided by operating activities:
Depreciation	4,231	3,566
Amortization	18,910	25,336
Stock-based compensation expense	2,234	4,275
Amortization of debt issuance costs and discount	332	1,345
Deferred income tax benefit	(864)	(483)
Other	(744)	(207)
Changes in assets and liabilities:
Accounts receivable and unbilled, net	3,405	(24,825)
Prepaid expenses and other current assets	(519)	(8,551)
Accounts payable	(2,855)	(2,112)
Accrued expenses	(8,398)	(1,461)
Pre-funded study costs	(3,510)	2,372
Advanced billings	(294)	15,017
Other assets and liabilities, net	(195)	(2,191)
Net cash provided by operating activities	29,733	20,491
CASH FLOWS FROM INVESTING ACTIVITIES:
Property and equipment expenditures	(6,019)	(5,693)
Acquisition of intangibles	(515)	0
Other	29	40
Net cash used in investing activities	(6,505)	(5,653)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from stock option exercises	955	102
Repurchases of common stock	(26,405)	0
Payment of debt	(6,187)	(15,036)
Payment of deemed landlord liability	(813)	(744)
Net cash used in financing activities	(32,450)	(15,678)
EFFECT OF EXCHANGE RATES ON CASH, CASH EQUIVALENTS, AND RESTRICTED CASH	1,145	143
DECREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH	(8,077)	(697)
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — Beginning of period	37,407	17,737
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — End of period	$ 29,330	$ 17,040

Basis of Presentation

6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

Basis of Presentation

(1) Basis of Presentation

Description of Business

Medpace Holdings, Inc. together with its subsidiaries, (“Medpace” or the “Company”), a Delaware corporation, is a global provider of clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials.

The Company’s operations are principally based in North America, Europe, and Asia.

Unaudited Interim Financial Information

The interim condensed consolidated financial statements include the accounts of the Company, are prepared in conformity with U.S. generally accepted accounting principles (“GAAP”), and are unaudited. In the opinion of the Company’s management, all adjustments of a normal recurring nature necessary for a fair presentation have been reflected. Certain financial information that is normally included in annual financial statements prepared in accordance with GAAP, but that is not required for interim reporting purposes, has been omitted. The preparation of the interim condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the interim condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results and outcomes could differ from management’s estimates and assumptions. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the Company’s audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016.

Share Repurchases

In April 2017, the Board of Directors (the “Board”) of the Company authorized a share repurchase program with an authorized repurchase level of $50.0 million. The share repurchase program, according to its terms, will expire in April 2018. Repurchases under the repurchase program may take place in the open market or negotiated transactions, at the discretion of the Company’s management. During the three and six months ended June 30, 2017, the Company repurchased 1,042,455 shares of its outstanding common stock for $26.4 million.

Recently Adopted Accounting Standards

In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-01, Business Combinations. The standard changes the definition of a business to assist entities with evaluating when a set of transferred assets and activities is a business. Under the new guidance, an entity first determines whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets. If this threshold is met, the set is not a business. If it’s not met, the entity then evaluates whether the set meets the requirement that a business include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs. ASU 2017-01 is effective for fiscal years beginning after December 15, 2017, and for interim periods within those fiscal years. The Company, as permitted, early adopted ASU 2017-01 using the prospective method in the second quarter of 2017. ASU 2017-01 was considered in the asset acquisition described in Note 2.

In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. The new guidance is intended to reduce diversity in practice by requiring the statement of cash flows to explain the change during the period in the total of cash, cash equivalents and amounts generally described as restricted cash and restricted cash equivalents. ASU 2016-18 is effective for fiscal years beginning after December 15, 2017, and for interim periods within those fiscal years. The Company, as permitted, early adopted ASU 2016-18 in the fourth quarter of 2016. As a result of this adoption, cash flows resulting from changes in restricted cash balances, are no longer presented as a component of net cash provided by operating activities in the Company’s condensed consolidated statements of cash flows, but have been reclassified and combined within Increases/(Decreases) in Cash and Cash Equivalents and Restricted Cash. This reclassification was retrospectively applied to all periods presented within the condensed consolidated statements of cash flows.

In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting. The new guidance is intended to simplify certain aspects of accounting for share based payments to employees, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The Company elected to adopt this ASU in the first quarter of 2017 as required. The following summarizes the effects of the adoption on the Company's condensed consolidated financial statements:

•

Income taxes - Upon adoption of this standard, all excess tax benefits and tax deficiencies (including tax benefits of dividends, if distributed, on share-based payment awards) are recognized as income tax expense or benefit in the statement of operations. The tax effects of exercised or vested awards are treated as discrete items in the reporting period in which they occur. As a result, the Company recognized discrete adjustments to income tax expense for the six months ended June 30, 2017 of less than $0.1 million related to excess tax benefits. The Company also recognizes excess tax benefits regardless of whether the benefit reduces taxes payable in the current period. The Company applied the prospective adoption approach for any unrecognized excess tax benefits beginning in 2017, which did not result in any cumulative-effect adjustment upon adoption. Prior periods have not been adjusted.

•

Forfeitures - Prior to adoption, share-based compensation expense was recognized on a straight line basis, net of estimated forfeitures, such that expense was recognized only for share-based awards that were expected to vest. A forfeiture rate was estimated annually and revised, if necessary, in subsequent periods if actual forfeitures differed from initial estimates. Upon adoption, the Company no longer applies a forfeiture rate and instead accounts for forfeitures as they occur. The Company applied the modified retrospective adoption approach beginning in 2017 and booked an immaterial cumulative-effect adjustment to additional paid-in-capital and retained earnings within Shareholders’ Equity. Prior periods have not been adjusted.

•

Statements of Cash Flows - The Company historically accounted for excess tax benefits on the Statement of Cash Flows as a financing activity. Upon adoption of this standard, excess tax benefits are classified along with other income tax cash flows as an operating activity. The Company elected to adopt this portion of the standard on a prospective basis beginning in 2017. Prior periods have not been adjusted.

•

Earnings Per Share - The Company uses the treasury stock method to compute diluted earnings per share, unless the effect would be anti-dilutive. Under this method, the Company is no longer required to estimate the tax rate and apply it to the dilutive share calculation for determining the dilutive earnings per share. The Company utilized the prospective adoption approach and applied this methodology beginning in 2017. Prior periods have not been adjusted.

Upon adoption, no other aspects of ASU 2016-09 had an effect on the Company's condensed consolidated financial statements or related footnote disclosures.

Recently Issued Accounting Standards

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The guidance in ASU 2016-02 supersedes the lease recognition requirements in ASC Topic 840, Leases (FAS 13). ASU 2016-02 requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases, along with additional qualitative and quantitative disclosures. ASU 2016-02 will be applied on a modified retrospective basis to each prior reporting period presented and is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the effect this standard will have on its condensed consolidated financial statements.

In May 2014, the FASB issued ASU No. 2014-09 ‘‘Revenue from Contracts with Customers,’’ to clarify the principles of recognizing revenue and create common revenue recognition guidance between US GAAP and International Financial Reporting Standards. In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net). In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. In May 2016, the FASB issued ASU 2016-12, Narrow-Scope Improvements and Practical Expedients. In December 2016, the FASB issued ASU 2016-20 Technical Corrections and Improvements to Topic 606, Revenue From Contracts with Customers. ASUs’ 2016-20, 2016-12, 2016-10 and 2016-08 all clarify the interpretation guidance in ASU No. 2014-09, “Revenue from Contracts with Customers” specifically related to narrowing specific aspects of Topic 606 and adding illustrative examples to assist in the application of the guidance. The effective date and transition requirements in ASUs’ 2016-20, 2016-12, 2016-10, and 2016-08 are the same as the effective date and transition requirements of ASU 2014-09. ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, deferred the original effective date of ASU 2014-09 by one year. The new standard allows for either a retrospective or modified retrospective approach to transition upon adoption. The new standard will be effective for annual reporting periods beginning after December 15, 2017. Early adoption is permitted for annual reporting periods beginning after December 15, 2016.

The Company continues to progress in its evaluation of potential impact of adopting this standard on its business policies, processes and systems, internal control over financial reporting environment, and financial reporting and disclosures. The Company expects that the majority of its contracts will have a single performance obligation and continues to assess the best measure of progress for recognition purposes. The Company will adopt ASU 2014-09 as well as the clarified guidance in ASUs’ 2016-20, 2016-12, 2016-10, 2016-08, utilizing the modified retrospective approach, during the first quarter of 2018.

Acquisition	6 Months Ended
Acquisition	Jun. 30, 2017
Asset Acquisition [Abstract]
Acquisition	(2) Acquisition In May 2017, the Company acquired out of bankruptcy NephroGenex, Inc. (“Nephrogenex” or the “Debtor”), a publicly-held pharmaceutical company that had previously filed for relief under Chapter 11 of the United States Bankruptcy Code. The Company, which was the largest unsecured creditor of Nephrogenex, entered into an agreement through the bankruptcy process, to exchange its unsecured claim for 100% of the common stock in the post-bankruptcy, debt free Debtor. The assets of the acquired Debtor consist primarily of tax attributes as well as in-process research and development and other intangible assets. An analysis by the Company determined that substantially all the fair value of the assets on the date of acquisition is captured in the tax attributes, as the intangible assets account for a relatively immaterial portion of the fair market value of the total assets received. The acquisition of the Debtor was accounted for as an asset purchase. The Company allocated its consideration paid of $1.2 million, consisting of accounts receivable and unbilled receivables and transaction related costs, on a pro rata basis to the assets acquired based on their respective fair values. Acquired assets include intangible assets of $0.5 million, deferred tax assets of $22.2 million, consisting of tax effected net operating losses in the amount of $21.1 (partially offset with a $7.6 million valuation allowance), tax effected capitalized research and development expenses of $8.5 million and tax effected federal tax credits of $1.4 million (partially offset with a $1.2 million valuation allowance) and deferred tax liabilities of $0.1 million. The excess amount of fair value received over consideration paid of $21.4 million was recorded as a Deferred credit in the condensed consolidated balance sheets and will be recognized within Income tax provision in proportion to the realization of the deferred tax assets and federal tax credits prospectively.

Net Income Per Share

6 Months Ended

Jun. 30, 2017

Earnings Per Share [Abstract]

Net Income Per Share

(3) Net Income Per Share

Basic and diluted earnings or loss per share (“EPS”) are computed using the two-class method, which is an earnings allocation that determines EPS for each class of common stock and participating securities according to dividends declared and participation rights in undistributed earnings. Restricted Stock Awards (“RSAs”) are considered participating securities because they are legally issued at the date of grant and holders are entitled to receive non-forfeitable dividends during the vesting term.

The computation of diluted EPS includes additional common shares, such as unvested stock options with exercise prices less than the average market price of the Company’s common stock during the period (“in-the-money options”), which would be considered outstanding under the treasury stock method. The treasury stock method assumes that additional shares would have to be issued in cases where the exercise price of stock options is less than the value of the common stock being acquired because the cash proceeds received from the stock option holder would not be sufficient to acquire that same number of shares. The Company does not compute diluted EPS in cases where the inclusion of such additional shares would be anti-dilutive in effect.

The following table sets forth the computation of basic and diluted earnings per share for the three and six months ended June 30, 2017 and 2016, (in thousands, except for earnings per share):


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2017		2016		2017		2016
Weighted-average shares:
Common shares outstanding		40,183		32,636		40,425		32,631
RSAs		59		-		59		-
Total weighted-average shares		40,242		32,636		40,484		32,631
Earnings per common share—Basic
Net income	$	9,553	$	4,962	$	18,000	$	8,410
Less: Undistributed earnings allocated to RSAs		14		-		26		-
Net income available to common shareholders—Basic	$	9,539	$	4,962	$	17,974	$	8,410

Net income per common share—Basic	$	0.24	$	0.15	$	0.44	$	0.26

Basic weighted-average common shares outstanding		40,183		32,636		40,425		32,631
Effect of diluted shares		642		192		733		-
Diluted weighted-average shares outstanding		40,825		32,828		41,158		32,631

Net income per common share—Diluted	$	0.23	$	0.15	$	0.44	$	0.26

During the three months ended June 30, 2017, there were 15,030 shares excluded from the computation of EPS because they were anti-dilutive under the treasury method calculation of diluted weighted average shares outstanding. During the six months ended June 30, 2017 and 2016, respectively, there were 46,124 and 25,584 shares excluded from the computation of EPS because they were anti-dilutive under the treasury method calculation of diluted weighted average shares outstanding.

During the three months ended June 30, 2017, there were 697,850 stock options that were excluded from the computation of EPS due to the exercise price exceeding the average fair value of the Company’s common stock during the period. During the six months ended June 30, 2017 and 2016, respectively, there were 27,500 and 186,667 stock options that were excluded from the computation of EPS due to the exercise price exceeding the average fair value of the Company’s common stock during the period.

Fair Value Measurements	6 Months Ended
Fair Value Measurements	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	(4) Fair Value Measurements The Company follows accounting guidance related to fair value measurements that defines fair value, establishes a framework for measuring fair value, and establishes a hierarchy for inputs used in measuring fair value. This hierarchy maximizes the use of “observable” inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. The hierarchy specifies three levels based on the inputs, as follows: Level 1: Valuations based on quoted prices in active markets for identical assets or liabilities. Level 2: Valuations based on directly observable inputs or unobservable inputs corroborated by market data. Level 3: Valuations based on unobservable inputs supported by little or no market activity representing management’s determination of assumptions of how market participants would price the assets or liabilities. The fair value of financial instruments such as cash and cash equivalents, accounts receivable and unbilled, net, accounts payable, accrued expenses and advanced billings approximate their carrying amounts due to their short term maturities. The Company does not have any recurring fair value measurements as of June 30, 2017. There were no transfers between Level 1, Level 2 or Level 3 during the three or six months ended June 30, 2017 and 2016.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Accounts Receivable And Unbilled, Net

6 Months Ended

Jun. 30, 2017

Receivables [Abstract]

Accounts Receivable And Unbilled, Net

(5) Accounts Receivable And Unbilled, Net

Accounts receivable and unbilled, net includes service revenue and reimbursed out-of-pocket revenue. Accounts receivable and unbilled, net consisted of the following (in thousands):

	As of
	June 30,		December 31,
	2017		2016
Accounts receivable	$	50,606	$	48,270
Unbilled	28,164			34,719
Less allowance for doubtful accounts	(2,106)		(3,222)
Total accounts receivable and unbilled, net	$	76,664	$	79,767

- Definition

The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.

+ References + Details

Intangible Assets, Net

6 Months Ended

Jun. 30, 2017

Goodwill And Intangible Assets Disclosure [Abstract]

Intangible Assets, Net

(6) Intangible Assets, Net

Intangible assets, net consisted of the following (in thousands):

	As of
	June 30,			December 31,
	2017			2016
Intangible assets:
Finite-lived intangible assets:
Carrying amount:
Backlog	$	72,630		$	72,630
Customer relationships		145,051			145,051
Developed technologies		54,475			54,475
Other		3,020			2,505
Total finite-lived intangible assets		275,176			274,661
Accumulated amortization:
Backlog		(72,630	)		(72,630	)
Customer relationships		(79,464	)		(66,267	)
Developed technologies		(35,409	)		(29,961	)
Other		(1,643	)		(1,378	)
Total accumulated amortization		(189,146	)		(170,236	)
Total finite-lived intangible assets, net		86,030			104,425
Trade name (indefinite-lived)		31,646			31,646
Total intangible assets, net	$	117,676		$	136,071

As of June 30, 2017, estimated amortization expense of the Company’s intangible assets for each of the next five years and thereafter is as follows (in thousands):

	Amortization
Remainder of 2017	$	18,981
2018		29,543
2019		14,810
2020		7,869
2021		5,114
Later years		9,713
	$	86,030

Accrued Expenses

6 Months Ended

Jun. 30, 2017

Payables And Accruals [Abstract]

Accrued Expenses

(7) Accrued Expenses

Accrued expenses consisted of the following (in thousands):

	As of
	June 30,		December 31,
	2017		2016
Employee compensation and benefits	$	13,191	$	21,453
Other		3,201		2,964
Total accrued expenses	$	16,392	$	24,417

Debt

6 Months Ended

Jun. 30, 2017

Debt Disclosure [Abstract]

Debt

(8) Debt

Debt consisted of the following (in thousands):

	As of
	June 30,			December 31,
	2017			2016

Term loan	$	158,813		$	165,000
Less unamortized discount		(466	)		(534	)
Less unamortized term loan debt issuance costs		(718	)		(824	)
Less current portion of long-term debt		(14,438	)		(12,375	)
Long-term debt, net, less current portion	$	143,191		$	151,267

Principal payments on debt are due as follows (in thousands):

2017 (remaining)	$	6,188
2018		16,500
2019		16,500
2020		20,625
2021		99,000
Total	$	158,813

The estimated fair value of the Company’s term loan based on Level 2 inputs using the market approach, which is primarily based on rates at which the debt is traded among financial institutions, approximates the carrying value as of June 30, 2017 and December 31, 2016.

Shareholder's Equity and Stock-Based Compensation

6 Months Ended

Jun. 30, 2017

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Shareholder's Equity and Stock-Based Compensation

(9) Shareholder’s Equity and Stock-Based Compensation

The Company granted 27,500 and 727,550 stock option awards, vesting after four years, to employees under the 2016 Incentive Award Plan, during the three and six months ended June 30, 2017. The Company granted an additional 41,346 stock option awards, vesting after one year, to non-employee directors under the 2016 Incentive Award Plan, during the three and six months ended June 30, 2017. The Company granted 34,812 stock options vesting equally over four years and 11,111 restricted awards, which immediately vested upon issuance, to employees under the 2014 Equity Incentive Plan during the six months ended June 30, 2016.

Award Activity

The following table sets forth the Company’s stock option activity:

	Six Months Ended June 30, 2017
				Weighted Average
	Stock Options			Exercise Price
Outstanding - beginning of period		2,350,166		$	17.57
Granted		768,896		$	28.35
Exercised		(72,579	)	$	15.24
Forfeited/Expired		(125,707	)	$	20.80
Outstanding - end of period		2,920,776		$	20.32

Exercisable - end of period		859,212		$	15.34

The following table sets forth the Company’s Restricted Share activity:

	Six Months Ended
	June 30, 2017
	Shares
Outstanding and unvested - beginning of period		59,258
Granted		-
Vested		-
Forfeited		-
Outstanding and unvested - end of period		59,258

Cumulative vested shares - end of period		1,854,658

Stock-based compensation expense recognized in the condensed consolidated statements of operations related to all outstanding stock based compensation awards is summarized below (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Direct costs, excluding depreciation and amortization	$	573	$	1,911	$	1,115	$	2,474
Selling, general and administrative		627		1,355		1,119		1,801
Total stock-based compensation expense	$	1,200	$	3,266	$	2,234	$	4,275

Income Taxes	6 Months Ended
Income Taxes	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Income Taxes	(10) Income Taxes The Company’s effective income tax rate was 33.4% and 36.0% for the three and six months ended June 30, 2017, respectively. The Company’s effective income tax rate was 39.4% and 40.6% for the three and six months ended June 30, 2016, respectively. The Company’s effective income tax rate for the three and six months ended June 30, 2017 varied from the U.S. statutory rate of 35.0% primarily due to the impact of state taxes, domestic and foreign uncertain tax positions and the tax impact associated with acquired tax attributes. The Company acquired deferred tax assets of $22.2 million, consisting of tax effected net operating losses in the amount of $21.1 (partially offset with a $7.6 million valuation allowance), tax effected capitalized research and development expenses of $8.5 million and tax effected federal tax credits of $1.4 million (partially offset with a $1.2 million valuation allowance) and deferred tax liabilities of $0.1 million. See Note 2 for further description of the asset acquisition that occurred in the second quarter of 2017.

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Jun. 30, 2017
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	(11) Commitments and Contingencies Legal Proceedings The Company is involved in legal proceedings from time to time in the ordinary course of its business, including employment claims and claims related to other business transactions. The Company cannot predict with certainty the outcome of such proceedings, but it believes that adequate reserves have been recorded and losses already recognized with respect to such actions were immaterial as of June 30, 2017 and December 31, 2016. There is a reasonable possibility that a loss exceeding amounts already recognized may be incurred related to these actions; however, the Company believes that such potential losses were immaterial as of June 30, 2017.

Related Party Transactions	6 Months Ended
Related Party Transactions	Jun. 30, 2017
Related Party Transactions [Abstract]
Related Party Transactions	(12) Related Party Transactions Employee Loans The Company periodically extends short term loans or advances to employees, typically upon commencement of employment. Total receivables as a result of these employee advances of $0.2 million existed at June 30, 2017 and December 31, 2016, respectively, and are included in the Prepaid expenses and other current assets and Other assets line items of the condensed consolidated balance sheets, respectively, depending on the contractual repayment date. Management Fees In conjunction with the IPO, the Advisory Services Agreement with Cinven Capital Management (V) General Partner Limited (“Cinven”) expired. Subsequent to the IPO, the Company pays fees for director services provided by Cinven employees that are members of the Company’s Board of Directors and any related committees. The director fees are paid directly to Cinven in accordance with the Company’s non-employee director compensation policy. During the three and six months ended June 30, 2016, the Company incurred management fees to Cinven of $0.1 million and $0.2 million, respectively, in the Company’s condensed consolidated statements of operations. Service Agreements Symplmed Pharmaceuticals, LLC (“Symplmed”) Medpace Investors LLC, a noncontrolling shareholder of the Company that is owned by employees of the Company and managed by the Company’s chief executive officer, has a majority ownership interest in Symplmed, a private pharmaceutical development company. In addition, the chief executive officer and other executives of the Company are board members of Symplmed. The Company has operated under a Master Services Agreement (“MSA”) with Symplmed since 2013 (amended in 2014) to perform clinical trial related services. Certain task orders governed by this arrangement were amended in the third quarter of 2016, changing the fee structure from unitized in nature to time and materials and revised pricing to more appropriately reflect market pricing based on the Company’s leveraging of this work to develop and enhance certain new service capabilities. The Company has evaluated its relationship with Symplmed and concluded that Symplmed is not a variable interest entity because the Company has no direct ownership interest or relationship other than the MSA. During the three months ended June 30, 2017 and 2016, the Company recognized service revenue from Symplmed of less than $0.1 million and $0.1 million, respectively, and during the six months ended June 30, 2017 and 2016, the Company recognized service revenue from Symplmed of less than $0.1 million and $0.4 million, respectively, in the Company’s condensed consolidated statements of operations. Coherus BioSciences, Inc. (“Coherus”) The chief executive officer of the Company is a member of Coherus’s board of directors. During the three months ended June 30, 2017 and 2016, the Company recognized service revenue from Coherus of $1.8 million and $4.3 million, respectively, and during the six months ended June 30, 2017 and 2016, the Company recognized service revenue from Coherus of $5.1 million and $11.4 million, respectively, in the Company’s condensed consolidated statements of operations. In addition, the company recognized Reimbursed out-of-pocket revenue and Reimbursed out-of-pocket expenses with Coherus in the condensed consolidated statements of operations of $0.4 million and $1.6 million during the three months ended June 30, 2017 and 2016, respectively, and $1.0 million and $2.9 million during the six months ended June 30, 2017 and 2016. As of June 30, 2017 and December 31, 2016, respectively, the Company had Accounts receivable and unbilled, net from Coherus of $0.6 million and $2.0 million recorded in the condensed consolidated balance sheets. As of June 30, 2017 and December 31, 2016, respectively, the Company had, from Coherus, $3.7 million and $6.3 million of Advanced billings and $1.4 million and $3.8 million of Pre-funded study costs, in the condensed consolidated balance sheets. Xenon Pharmaceuticals, Inc. (“Xenon”) Certain executives and employees of the Company, including the chief executive officer, have held equity investments in Xenon, a clinical-stage biopharmaceutical company. During the second quarter of 2017, the chief executive officer sold his entire equity position held in Xenon. During July 2015 the Company and Xenon entered into an amended MSA agreement for the Company to provide clinical trial related services. The Company recognized service revenue from Xenon of $0.1 million and $0.1 million during the three months ended June 30, 2017 and 2016, respectively, and service revenue from Xenon of $0.6 million and $0.4 million during the six months ended June 30, 2017 and 2016, respectively, in the Company’s condensed consolidated statements of operations. As of June 30, 2017 and December 31, 2016, respectively, the Company had Accounts receivable and unbilled, net from Xenon of less than $0.1 million and $0.3 million recorded in the condensed consolidated balance sheets. As of June 30, 2017 and December 31, 2016, respectively, the Company had, from Xenon, $0.4 million and $1.3 million of Advanced billings and $0.1 million and $0.1 million of Pre-funded study costs, in the condensed consolidated balance sheets. Cymabay Therapeutics, Inc. (“Cymabay”) Cymabay is a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. During the first quarter of 2016, it was announced that a Medpace employee would join Cymabay’s board of directors. The Company and Cymabay entered into a MSA dated October 21, 2016. Subsequently, the Company and Cymabay have entered into several task orders for the Company to perform clinical trial related services. During the three months ended June 30, 2017 and 2016, the Company recognized service revenue from Cymabay of $0.2 million and $0.1 million, respectively, and during the six months ended June 30, 2017 and 2016, the Company recognized service revenue from Cymabay of $0.3 million and $0.2 million, respectively, in the Company’s condensed consolidated statements of operations. As of June 30, 2017 and December 31, 2016, respectively, the Company had Accounts receivable and unbilled, net from Cymabay of $0.1 million and less than $0.1 million recorded in the condensed consolidated balance sheets. LIB Therapeutics LLC (“LIB”) Certain executives and employees of the Company, including the chief executive officer, are members of LIB’s board of managers. The Company entered into a MSA dated November 24, 2015 with LIB, a company that engages in research, development, marketing and commercialization of pharmaceutical drugs. Subsequently, the Company and LIB have entered into several task orders for the Company to perform clinical trial related services. During the three months ended June 30, 2017 and 2016, the Company recognized service revenue from LIB of $0.5 million and less than $0.1 million, respectively, and during the six months ended June 30, 2017 and 2016, the Company recognized service revenue from LIB of $0.6 million and less than $0.1 million, respectively, in the Company’s condensed consolidated statements of operations. As of June 30, 2017 and December 31, 2016, respectively, the Company had Accounts receivable and unbilled, net from LIB of $0.3 million and less than $0.1 million recorded in the condensed consolidated balance sheets. CinRX Pharma, LLC (“CinRX”) Certain executives and employees of the Company, including the chief executive officer, are members of CinRX’s board of managers and/or have equity investments in CinRX, a biotech company. The Company and CinRX have entered into several task orders for the Company to perform clinical trial related services. During the three and six months ended June 30, 2017, the Company recognized service revenue from CinRX of $0.2 million, respectively, in the Company’s condensed consolidated statements of operations. Medpace Investors, LLC Medpace Investors is a noncontrolling shareholder and related party of Medpace Holdings, Inc. Medpace Investors is owned and managed by employees of the Company. The chief executive officer of Medpace is also the manager and majority unit holder of Medpace Investors. The Company acted as a paying agent for Medpace Investors with taxing authorities principally in instances when employee tax payments or remittance of withholdings related to equity compensation are required. During the three and six months ended June 30, 2016, the Company paid $0.2 million and $0.8 million to various taxing authorities on behalf of Medpace Investors. Purchase of Real Estate Properties In December 2016, the Company entered into a purchase agreement for four parcels of real estate property that are closely situated to the Medpace campus in Cincinnati, Ohio, from AT Redevelopment Company, LLC, which is wholly-owned by the Company’s chief executive officer. The purchase price of the real estate property was $0.4 million as determined by an independent third party broker's opinion of value. The transaction closed on January 11, 2017. Leased Real Estate Headquarters Lease The Company entered into an operating lease for its corporate headquarters with an entity that is wholly owned by the chief executive officer of the Company. The Company has evaluated its relationship with the related party and concluded that the related party is not a variable interest entity because the Company has no direct ownership interest or relationship other than the lease. The lease for headquarters is for an initial term of twelve years through November 2022 with a renewal option for one 10-year term at prevailing market rates. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the property. Annual base rent for the corporate headquarters allows for adjustments to the rental rate annually for increases in the consumer price index. Lease expense recognized for each of the three months ended June 30, 2017 and 2016 was $0.6 million, respectively, and lease expense recognized for each of the six months ended June 30, 2017 and 2016 was $1.1 million, respectively. The lease expense was allocated between Direct costs, excluding depreciation and amortization, and Selling, general and administrative in the condensed consolidated statements of operations. Deemed Assets and Deemed Landlord Liabilities The Company entered into two multi-year lease agreements governing the occupancy of space of two buildings in Cincinnati, Ohio with an entity that is wholly owned by the Company’s chief executive officer and certain members of his immediate family. In accordance with the accounting guidance related to leases, the Company was deemed in substance to be the owner of the property during the construction phase and at completion. Accordingly, the Company reflected the buildings and related liabilities as deemed assets from landlord building construction in Property and equipment, net, Other current liabilities, and Deemed landlord liability, less current portion, respectively, on the condensed consolidated balance sheets. The Company assumed occupancy in 2012 and the leases expire in 2027 with the Company having one 10-year option to extend the lease term. The deemed assets are being fully depreciated, on a straight line basis, over the 15-year term of the lease. Deemed landlord liabilities are recorded at their net present value when the Company enters into qualifying leases and are reduced as the Company makes periodic lease payments on the properties. Accretion expense is being recorded over the term of the lease as a component of Interest expense, net in the Company’s condensed consolidated statements of operations. The Company paid $1.0 million during the three months ended June 30, 2017 and 2016, respectively, and $1.9 million during the six months ended June 30, 2017 and 2016. The current and long-term portions of the Deemed landlord liability at June 30, 2017 were $1.8 million and $27.6 million, respectively. The current and long-term portions of the Deemed landlord liability at December 31, 2016 were $1.7 million and $28.5 million, respectively. The Company has recognized deemed assets, net of $17.2 million and $18.1 million at June 30, 2017 and December 31, 2016, respectively, in the condensed consolidated balance sheets. Travel Services The Company incurs expenses for travel services for company executives provided by a private aviation charter company that is owned by the chief executive officer and the executive vice president of operations of the Company (“private aviation charter”). The Company may contract directly with the private aviation charter for the use of its aircraft or indirectly through a third party aircraft management and jet charter company (the “Aircraft Management Company”). The travel services provided are primarily for business purposes, with certain personal travel paid for as part of the executives’ compensation arrangements. The Aircraft Management Company also makes the private aviation charter aircraft available to third parties. The Company incurred travel expenses of $0.3 million and $0.2 million during the three months ended June 30, 2017 and 2016, respectively, and $0.6 million and $0.5 during the six months ended June 30, 2017 and 2016, respectively, related to these travel services. These travel expenses are recorded in Selling, general and administrative in the Company’s condensed consolidated statements of operations.

Cash Flow Statement- Supplemental Information

6 Months Ended

Jun. 30, 2017

Supplemental Cash Flow Information [Abstract]

Cash Flow Statement- Supplemental Information

(13) Cash Flow Statement- Supplemental Information

During the six months ended June 30, 2017, the Company engaged in the following significant non-cash investing and financing activities:

•

Acquired net assets totaling $0.7 million consisting of net Deferred tax assets of $22.2 million, offset by net Deferred tax liabilities of $0.1 million and Deferred credits of $21.4 million in exchange for Accounts receivable and unbilled, net of $0.6 million and Other assets of $0.1 million.

Basis of Presentation (Policies)

6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

Unaudited Interim Financial Information

Share Repurchases

Recently Adopted and Issued Accounting Standards

Recently Adopted Accounting Standards

•

Upon adoption, no other aspects of ASU 2016-09 had an effect on the Company's condensed consolidated financial statements or related footnote disclosures.

Recently Issued Accounting Standards

Net Income Per Share (Tables)

6 Months Ended

Jun. 30, 2017

Earnings Per Share [Abstract]

Schedule of Reconciliation of Denominators and Additional Shares that are Excluded from the Calculation of EPS

The following table sets forth the computation of basic and diluted earnings per share for the three and six months ended June 30, 2017 and 2016, (in thousands, except for earnings per share):


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2017		2016		2017		2016
Weighted-average shares:
Common shares outstanding		40,183		32,636		40,425		32,631
RSAs		59		-		59		-
Total weighted-average shares		40,242		32,636		40,484		32,631
Earnings per common share—Basic
Net income	$	9,553	$	4,962	$	18,000	$	8,410
Less: Undistributed earnings allocated to RSAs		14		-		26		-
Net income available to common shareholders—Basic	$	9,539	$	4,962	$	17,974	$	8,410

Net income per common share—Basic	$	0.24	$	0.15	$	0.44	$	0.26

Basic weighted-average common shares outstanding		40,183		32,636		40,425		32,631
Effect of diluted shares		642		192		733		-
Diluted weighted-average shares outstanding		40,825		32,828		41,158		32,631

Net income per common share—Diluted	$	0.23	$	0.15	$	0.44	$	0.26

Accounts Receivable And Unbilled, Net (Tables)

6 Months Ended

Jun. 30, 2017

Receivables [Abstract]

Schedule of Accounts Receivable and Unbilled, Net

Accounts receivable and unbilled, net consisted of the following (in thousands):

	As of
	June 30,		December 31,
	2017		2016
Accounts receivable	$	50,606	$	48,270
Unbilled	28,164			34,719
Less allowance for doubtful accounts	(2,106)		(3,222)
Total accounts receivable and unbilled, net	$	76,664	$	79,767

Intangible Assets, Net (Tables)

6 Months Ended

Jun. 30, 2017

Goodwill And Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets, Net

Intangible assets, net consisted of the following (in thousands):

	As of
	June 30,			December 31,
	2017			2016
Intangible assets:
Finite-lived intangible assets:
Carrying amount:
Backlog	$	72,630		$	72,630
Customer relationships		145,051			145,051
Developed technologies		54,475			54,475
Other		3,020			2,505
Total finite-lived intangible assets		275,176			274,661
Accumulated amortization:
Backlog		(72,630	)		(72,630	)
Customer relationships		(79,464	)		(66,267	)
Developed technologies		(35,409	)		(29,961	)
Other		(1,643	)		(1,378	)
Total accumulated amortization		(189,146	)		(170,236	)
Total finite-lived intangible assets, net		86,030			104,425
Trade name (indefinite-lived)		31,646			31,646
Total intangible assets, net	$	117,676		$	136,071

Schedule of Estimated Amortization Expense of Intangible Assets

As of June 30, 2017, estimated amortization expense of the Company’s intangible assets for each of the next five years and thereafter is as follows (in thousands):

	Amortization
Remainder of 2017	$	18,981
2018		29,543
2019		14,810
2020		7,869
2021		5,114
Later years		9,713
	$	86,030

Accrued Expenses (Tables)

6 Months Ended

Jun. 30, 2017

Payables And Accruals [Abstract]

Schedule of Accrued Expenses

Accrued expenses consisted of the following (in thousands):

	As of
	June 30,		December 31,
	2017		2016
Employee compensation and benefits	$	13,191	$	21,453
Other		3,201		2,964
Total accrued expenses	$	16,392	$	24,417

Debt (Tables)

6 Months Ended

Jun. 30, 2017

Debt Disclosure [Abstract]

Schedule of Debt

Debt consisted of the following (in thousands):

	As of
	June 30,			December 31,
	2017			2016

Term loan	$	158,813		$	165,000
Less unamortized discount		(466	)		(534	)
Less unamortized term loan debt issuance costs		(718	)		(824	)
Less current portion of long-term debt		(14,438	)		(12,375	)
Long-term debt, net, less current portion	$	143,191		$	151,267

Schedule of Principal Payments on Debt Due

Principal payments on debt are due as follows (in thousands):

2017 (remaining)	$	6,188
2018		16,500
2019		16,500
2020		20,625
2021		99,000
Total	$	158,813

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21521-112644

+ Details

Shareholder's Equity and Stock-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2017

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Schedule of Stock Option Activity

The following table sets forth the Company’s stock option activity:

	Six Months Ended June 30, 2017
				Weighted Average
	Stock Options			Exercise Price
Outstanding - beginning of period		2,350,166		$	17.57
Granted		768,896		$	28.35
Exercised		(72,579	)	$	15.24
Forfeited/Expired		(125,707	)	$	20.80
Outstanding - end of period		2,920,776		$	20.32

Exercisable - end of period		859,212		$	15.34

Schedule of Restricted Share Activity

The following table sets forth the Company’s Restricted Share activity:

	Six Months Ended
	June 30, 2017
	Shares
Outstanding and unvested - beginning of period		59,258
Granted		-
Vested		-
Forfeited		-
Outstanding and unvested - end of period		59,258

Cumulative vested shares - end of period		1,854,658

Summary of Stock-Based Compensation Expense Recognized in Statements of Operations Related to All Outstanding Stock Based Compensation Awards

Stock-based compensation expense recognized in the condensed consolidated statements of operations related to all outstanding stock based compensation awards is summarized below (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Direct costs, excluding depreciation and amortization	$	573	$	1,911	$	1,115	$	2,474
Selling, general and administrative		627		1,355		1,119		1,801
Total stock-based compensation expense	$	1,200	$	3,266	$	2,234	$	4,275

Basis of Presentation - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended	6 Months Ended
	Apr. 30, 2017	Jun. 30, 2017	Jun. 30, 2017	Jun. 30, 2016
Basis Of Presentation [Line Items]
Stock repurchase program, expiration date	2018-04
Repurchases of outstanding common stock, shares		1,042,455	1,042,455
Repurchases of outstanding common stock		$ 26,400,000	$ 26,405,000	$ 0
Maximum
Basis Of Presentation [Line Items]
Stock repurchase program, authorized amount	$ 50,000,000
Maximum \| Accounting Standard Update (“ASU”) No. 2016-09
Basis Of Presentation [Line Items]
Discrete adjustments to income tax expense recognized			$ 100,000

Acquisition - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	6 Months Ended
	May 31, 2017	Jun. 30, 2017
Noncash Or Part Noncash Acquisitions [Line Items]
Deferred tax assets		$ 22,200
Deferred tax liabilities		100
Deferred credit		$ 21,420
NephroGenex, Inc.
Noncash Or Part Noncash Acquisitions [Line Items]
Bankruptcy proceedings unsecured claim in exchange of common stock percentage	100.00%
Consideration paid	$ 1,200
Intangible assets	500
Deferred tax assets	22,200
Tax effected net operating losses	21,100
Tax effected net operating losses, valuation allowance	7,600
Tax effected capitalized research and development expenses	8,500
Tax effected federal tax credits	1,400
Tax effected federal tax credits, valuation allowance	1,200
Deferred tax liabilities	100
Deferred credit	$ 21,400

Net Income Per Share - Schedule of Reconciliation of Denominators and Additional Shares that are Excluded from the Calculation of EPS (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Weighted-average shares:
Basic weighted-average common shares outstanding	40,183	32,636	40,425	32,631
Total weighted-average shares	40,242	32,636	40,484	32,631
Earnings per common share—Basic
Net income	$ 9,553	$ 4,962	$ 18,000	$ 8,410
Net income available to common shareholders—Basic	$ 9,539	$ 4,962	$ 17,974	$ 8,410
Net income per common share—Basic	$ 0.24	$ 0.15	$ 0.44	$ 0.26
Basic weighted-average common shares outstanding	40,183	32,636	40,425	32,631
Effect of diluted shares	642	192	733	0
Diluted weighted-average shares outstanding	40,825	32,828	41,158	32,631
Net income per common share—Diluted	$ 0.23	$ 0.15	$ 0.44	$ 0.26
RSAs
Weighted-average shares:
Basic weighted-average common shares outstanding	59	0	59	0
Earnings per common share—Basic
Less: Undistributed earnings allocated to RSAs	$ 14	$ 0	$ 26	$ 0
Basic weighted-average common shares outstanding	59	0	59	0
Common Stock
Weighted-average shares:
Basic weighted-average common shares outstanding	40,183	32,636	40,425	32,631
Earnings per common share—Basic
Basic weighted-average common shares outstanding	40,183	32,636	40,425	32,631

Net Income Per Share - Additional Information (Details) - shares shares in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2017	Jun. 30, 2016
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted EPS	15,030	46,124	25,584
Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted EPS	697,850	27,500	186,667

Fair Value Measurements - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Fair Value Disclosures [Abstract]
Fair value measurements transfers between level 1, level 2, or level 3	$ 0	$ 0	$ 0	$ 0

Accounts Receivable And Unbilled, Net - Schedule of Accounts Receivable and Unbilled, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Accounts Notes And Loans Receivable Net Current [Abstract]
Accounts receivable	$ 50,606	$ 48,270
Unbilled	28,164	34,719
Less allowance for doubtful accounts	(2,106)	(3,222)
Total accounts receivable and unbilled, net	$ 76,664	$ 79,767

Intangible Assets, Net - Schedule of Intangible Assets, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Finite-lived intangible assets:
Total finite-lived intangible assets	$ 275,176	$ 274,661
Accumulated amortization:
Total accumulated amortization	(189,146)	(170,236)
Total finite-lived intangible assets, net	86,030	104,425
Trade name (indefinite-lived)	31,646	31,646
Total intangible assets, net	117,676	136,071
Backlog
Finite-lived intangible assets:
Total finite-lived intangible assets	72,630	72,630
Accumulated amortization:
Total accumulated amortization	(72,630)	(72,630)
Customer Relationships
Finite-lived intangible assets:
Total finite-lived intangible assets	145,051	145,051
Accumulated amortization:
Total accumulated amortization	(79,464)	(66,267)
Developed Technologies
Finite-lived intangible assets:
Total finite-lived intangible assets	54,475	54,475
Accumulated amortization:
Total accumulated amortization	(35,409)	(29,961)
Other
Finite-lived intangible assets:
Total finite-lived intangible assets	3,020	2,505
Accumulated amortization:
Total accumulated amortization	$ (1,643)	$ (1,378)

Intangible Assets, Net - Schedule of Estimated Amortization Expense of Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Remainder of 2017	$ 18,981
2018	29,543
2019	14,810
2020	7,869
2021	5,114
Later years	9,713
Total finite-lived intangible assets, net	$ 86,030	$ 104,425

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Accrued Liabilities And Other Liabilities [Abstract]
Employee compensation and benefits	$ 13,191	$ 21,453
Other	3,201	2,964
Total accrued expenses	$ 16,392	$ 24,417

Debt - Schedule of Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Debt Disclosure [Abstract]
Term loan	$ 158,813	$ 165,000
Less unamortized discount	(466)	(534)
Less unamortized term loan debt issuance costs	(718)	(824)
Less current portion of long-term debt	(14,438)	(12,375)
Long-term debt, net, less current portion	$ 143,191	$ 151,267

Debt - Schedule of Principal Payments on Debt Due (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Debt Disclosure [Abstract]
2017 (remaining)	$ 6,188
2018	16,500
2019	16,500
2020	20,625
2021	99,000
Term loan	$ 158,813	$ 165,000

Shareholder's Equity and Stock-Based Compensation - Additional Information (Details) - shares	3 Months Ended	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2017	Jun. 30, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted		768,896
Restricted Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares granted		0
2016 Incentive Award Plan \| Vesting After Four Years
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted	27,500	727,550
Award vesting period	4 years	4 years
2016 Incentive Award Plan \| Vesting After One Year \| Non-employee Directors
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted	41,346	41,346
Award vesting period	1 year	1 year
2014 Equity Incentive Plan \| Restricted Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares granted			11,111
2014 Equity Incentive Plan \| Vesting Equally Over Four Years
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted			34,812
Award vesting period			4 years

Shareholder's Equity and Stock-Based Compensation - Schedule of Stock Option Activity (Details) - $ / shares	6 Months Ended
	Jun. 30, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Stock Options, Outstanding - beginning of period	2,350,166
Number of Stock Options, Granted	768,896
Number of Stock Options, Exercised	(72,579)
Number of Stock Options, Forfeited/Expired	(125,707)
Number of Stock Options, Outstanding - end of period	2,920,776
Number of Stock Options, Exercisable - end of period	859,212
Weighted average exercise price, Outstanding - beginning of period	$ 17.57
Weighted average exercise price, Granted	28.35
Weighted average exercise price, Exercised	15.24
Weighted average exercise price, Forfeited/Expired	20.80
Weighted average exercise price, Outstanding - end of period	20.32
Weighted average exercise price, Exercisable - end of period	$ 15.34

Shareholder's Equity and Stock-Based Compensation - Schedule of Restricted Share Activity (Details) - Restricted Awards	6 Months Ended
	Jun. 30, 2017 shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding and unvested - beginning of period	59,258
Granted	0
Vested	0
Forfeited	0
Outstanding and unvested - end of period	59,258
Cumulative vested shares - end of period	1,854,658

Shareholder's Equity and Stock-Based Compensation - Summary of Stock-Based Compensation Expense Recognized in Statements of Operations Related to All Outstanding Stock Based Compensation Awards (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 1,200	$ 3,266	$ 2,234	$ 4,275
Direct Costs, Excluding Depreciation and Amortization
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	573	1,911	1,115	2,474
Selling, General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 627	$ 1,355	$ 1,119	$ 1,801

Income Taxes - Additional Information (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended		6 Months Ended
	May 31, 2017	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Income Tax Disclosure [Line Items]
Effective income tax rate		33.40%	39.40%	36.00%	40.60%
U.S. statutory rate		35.00%		35.00%
Deferred tax assets				$ 22.2
Deferred tax liabilities				$ 0.1
NephroGenex, Inc.
Income Tax Disclosure [Line Items]
Deferred tax assets	$ 22.2
Tax effected net operating losses	21.1
Tax effected net operating losses, valuation allowance	7.6
Tax effected capitalized research and development expenses	8.5
Tax effected federal tax credits	1.4
Tax effected federal tax credits, valuation allowance	1.2
Deferred tax liabilities	$ 0.1

Related Party Transactions - Additional Information (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2017 USD ($)	Jun. 30, 2016 USD ($)	Jun. 30, 2017 USD ($) RenewalOption Agreement Building	Jun. 30, 2016 USD ($)	Dec. 31, 2016 USD ($) Parcel
Related Party Transaction [Line Items]
Service revenue with related parties	$ 2,900,000	$ 4,600,000	$ 6,900,000	$ 12,400,000
Reimbursed out-of-pocket revenue with related parties	400,000	1,700,000	1,100,000	2,900,000
Accounts receivable and unbilled, net	1,200,000		1,200,000		$ 2,300,000
Advanced billings	4,200,000		4,200,000		7,600,000
Pre-funded study costs with related parties	1,500,000		1,500,000		3,900,000
Deemed landlord liability, long-term portions	27,591,000		27,591,000		28,527,000
Cinven
Related Party Transaction [Line Items]
Management fees expense with related party		100,000		200,000
Medpace Investors
Related Party Transaction [Line Items]
Related party tax expense		200,000		800,000
Employee Loans
Related Party Transaction [Line Items]
Employee advances receivables	200,000		200,000
Employee Loans \| Other Assets
Related Party Transaction [Line Items]
Employee advances receivables					200,000
Service Agreements \| Symplmed
Related Party Transaction [Line Items]
Service revenue with related parties				400,000
Service Agreements \| Symplmed \| Maximum
Related Party Transaction [Line Items]
Service revenue with related parties	100,000	100,000	100,000
Service Agreements \| Coherus Bio Sciences Inc
Related Party Transaction [Line Items]
Service revenue with related parties	1,800,000	4,300,000	5,100,000	11,400,000
Reimbursed out-of-pocket revenue with related parties	400,000	1,600,000	1,000,000	2,900,000
Accounts receivable and unbilled, net	600,000		600,000		2,000,000
Advanced billings	3,700,000		3,700,000		6,300,000
Pre-funded study costs with related parties	1,400,000		1,400,000		3,800,000
Service Agreements \| Xenon
Related Party Transaction [Line Items]
Service revenue with related parties	100,000	100,000	600,000	400,000
Accounts receivable and unbilled, net					300,000
Advanced billings	400,000		400,000		1,300,000
Pre-funded study costs with related parties	100,000		100,000		100,000
Service Agreements \| Xenon \| Maximum
Related Party Transaction [Line Items]
Accounts receivable and unbilled, net	100,000		100,000
Service Agreements \| Cymabay
Related Party Transaction [Line Items]
Service revenue with related parties	200,000	100,000	300,000	200,000
Accounts receivable and unbilled, net	100,000		100,000
Service Agreements \| Cymabay \| Maximum
Related Party Transaction [Line Items]
Accounts receivable and unbilled, net					100,000
Service Agreements \| LIB
Related Party Transaction [Line Items]
Service revenue with related parties	500,000		600,000
Accounts receivable and unbilled, net	300,000		300,000
Service Agreements \| LIB \| Maximum
Related Party Transaction [Line Items]
Service revenue with related parties		100,000		100,000
Accounts receivable and unbilled, net					$ 100,000
Service Agreements \| CinRX
Related Party Transaction [Line Items]
Service revenue with related parties	200,000		200,000
Purchase of Real Estate Properties \| Chief Executive Officer
Related Party Transaction [Line Items]
Number of parcel in real estate property \| Parcel					4
Purchase price of real estate property			$ 400,000
Transaction closed date			Jan. 11, 2017
Leased Real Estate \| Chief Executive Officer
Related Party Transaction [Line Items]
Term of lease			12 years
Lease expiration period			2022-11
Number of lease renewal, 10-year option \| RenewalOption			1
Lease term upon renewal			10 years
Lease expense recognized	600,000	600,000	$ 1,100,000	1,100,000
Leased Real Estate \| Chief Executive Officer And Immediate Family
Related Party Transaction [Line Items]
Term of lease			15 years
Number of lease renewal, 10-year option \| RenewalOption			1
Lease term upon renewal			10 years
Number of lease agreements \| Agreement			2
Number of buildings \| Building			2
Lease occupancy year			2012
Lease expiration year			2027
Accretion expense paid	1,000,000	1,000,000	$ 1,900,000	1,900,000
Deemed landlord liability, current	1,800,000		1,800,000		$ 1,700,000
Deemed landlord liability, long-term portions	27,600,000		27,600,000		28,500,000
Leased Real Estate \| Property and Equipment, Net \| Chief Executive Officer And Immediate Family \| Building
Related Party Transaction [Line Items]
Deemed assets, net	17,200,000		17,200,000		$ 18,100,000
Travel Services \| Chief Executive Officer
Related Party Transaction [Line Items]
Travel expenses with related party	$ 300,000	$ 200,000	$ 600,000	$ 500,000

Cash Flow Statement- Supplemental Information - Additional Information (Details)	6 Months Ended
	Jun. 30, 2017 USD ($)
Supplemental Cash Flow Information [Abstract]
Acquisition of net assets	$ 700
Deferred tax assets, net	22,200,000
Deferred tax liabilities, net	100,000
Deferred credits	21,400,000
Accounts receivable and unbilled, net	600,000
Other assets	$ 100,000